{"analyses":[{"ciLowerLimit":"0.40","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.05","estimateComment":"Reference level = TAS x 8 weeks","groupDescription":"Locoregional progression","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.07","paramType":"Hazard Ratio (HR)","paramValue":"0.65","statisticalComment":"2-sided significance level = 0.05","statisticalMethod":"Gray's test"},{"ciLowerLimit":"0.68","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.66","estimateComment":"Reference level = TAS x 8 weeks","groupDescription":"Distant metastasis","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.80","paramType":"Hazard Ratio (HR)","paramValue":"1.07","statisticalComment":"2-sided significance level = 0.05","statisticalMethod":"Gray's test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4","upperLimit":"8","value":"6"},{"groupId":"OG001","lowerLimit":"3","upperLimit":"6","value":"4"}]}],"title":"Locoregional progression"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4","upperLimit":"8","value":"6"},{"groupId":"OG001","lowerLimit":"4","upperLimit":"8","value":"6"}]}],"title":"Distant metastasis"}],"denoms":[{"counts":[{"groupId":"OG000","value":"752"},{"groupId":"OG001","value":"737"}],"units":"Participants"}],"description":"Time to distant metastasis measured from date of randomization to date of documented distant metastasis; competing risks are BF, LRP, and death without DM; all others are censored. Time to locoregional progression measured from date of randomization to date of documented local or regional progression; competing risks are BF \\[protocol definition- first of (1) the midway date between the last non-rising PSA and the first rising PSA of three consecutive rises or (2) the date of the initiation of salvage hormone therapy\\], DM, and death without LRP; all others are censored. LRP and DM are estimated using the cumulative incidence method. Ten -year rates are reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Total Androgen Suppression (TAS) (LHRH agonist and Casodex or Eulexin) x 8 weeks followed by radiation therapy (RT) with concurrent TAS (LHRH agonist and Casodex or Eulexin).","id":"OG000","title":"TAS x 8 Weeks"},{"description":"TAS (LHRH agonist and Casodex or Eulexin) x 28 weeks followed by RT with concurrent TAS (LHRH agonist and Casodex or Eulexin).","id":"OG001","title":"TAS x 28 Weeks"}],"paramType":"NUMBER","populationDescription":"Eligible patients with follow-up data","reportingStatus":"POSTED","timeFrame":"From randomization to 10 years. (Patients are followed until death or study termination, whichever occurs first.)","title":"Clinical Patterns of Tumor Recurrence: Time to Locoregional Progression (LRP) and Time to Distant Metastasis (DM) (10 Year Rates Reported)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}